Comparative Analysis of Neoadjuvant Immunochemotherapy and Neoadjuvant Targeted Therapy Combined with Chemotherapy in Patients with EGFR-Mutated Non-Small Cell Lung Cancer: A Retrospective Investigation - Top-Institutions - MDSpire

Comparative Analysis of Neoadjuvant Immunochemotherapy and Neoadjuvant Targeted Therapy Combined with Chemotherapy in Patients with EGFR-Mutated Non-Small Cell Lung Cancer: A Retrospective Investigation

  • By

  • Feng Li

  • Chaoqi Zhang

  • Luyu Huang

  • Ziming Wang

  • Guanchao Ye

  • Zhuoyu Gu

  • Yu Qi

  • January 20, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Thoracic Oncology
    • Molecular Oncology
    • Surgical Oncology

  • #2

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Thoracic Oncology
    • Immunotherapy
    • Targeted Therapy

  • #3

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Thoracic Oncology
    • Translational Cancer Research
    • Immunotherapy

  • #4

    Fudan University Shanghai Cancer Center
    Fudan University Shanghai Cancer Center

    Shanghai, Shanghai

    Key Differentiators

    • Thoracic Surgery
    • Lung Cancer Research
    • Targeted Therapy

  • #5

    National Cancer Center Hospital
    National Cancer Center Hospital

    Tokyo, Tokyo

    Key Differentiators

    • Thoracic Oncology
    • Molecular Targeted Therapy
    • Immunotherapy

Original Source(s)

Comparative Analysis of Neoadjuvant Immunochemotherapy and Neoadjuvant Targeted Therapy Combined with Chemotherapy in Patients with EGFR-Mutated Non-Small Cell Lung Cancer: A Retrospective Investigation

  • by Feng Li, Chaoqi Zhang, Luyu Huang, Ziming Wang, Guanchao Ye, Zhuoyu Gu, Yu Qi

  • January 20, 2026

Related Content

Characteristics and risk factors of immune-related adverse events in patients receiving immune checkpoint inhibitor combination therapy

The role of NAD+ metabolic reprogramming in colorectal cancer chemoresistance: mechanistic insights, clinical translation challenges and opportunities

Prospective phase II study of frontline Helicobacter pylori eradication therapy for early-stage extragastric mucosa-associated lymphoid tissue lymphoma